Drug Trial Radar · NCT03625037
First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma
Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
666
Actual
Start
Jun 26, 2018
Primary completion
Jan 2029
Study completion Jan 2029
Sponsor
- Lead sponsor
- GenmabIndustry
- Sponsor type
- Industry
- Collaborators
- AbbVie
- First posted
- Aug 10, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this trial is to measure the following in participants with relapsed and/or refractory B-cell lymphoma who receive epcoritamab, an antibody also known as EPKINLY™ and GEN3013 (DuoBody®-CD3xCD20): * The dose schedule for epcoritamab * The side effects seen with epcoritamab * What the body does with epcoritamab once it is administered * What epcoritamab does to the body once it is administered * How well epcoritamab works against relapsed and/or refractory B-cell lymphoma The trial consists of 3 parts: * a dose-escalation part (Phase 1, first-in-human \[FIH\]) * an expansion part (Phase 2a) * a dose-optimization part (OPT) (Phase 2a) The trial time for each participant depends on which trial part the participant enters: * For the dose-escalation part, each participant will be in the trial for approximately 1 year, which is made up of 21 days of screening, 6 months of treatment (the total time of treatment may be different for each participant), and 6 months of follow-up (the total time of follow-up may be different for each participant). * For the expansion and dose-OPT parts, each participant will be in the trial for approximately 1.5 years, which is made up of 21 days of screening, 1 year of treatment (the total time of treatment may be different for each participant), and 6 months of follow-up (the total time of follow-up may be different for each participant). Participation in the study will require visits to the sites. During the first month, participants must visit every day or every few days, depending on which trial part the participant enters. After that, participants must visit weekly, every other week, once a month, and once every 2 months, as trial participation ends. All participants will receive active drug, and no participants will be given placebo.
Conditions
- DLBCL
- High-grade B-cell Lymphoma (HGBCL)
- Primary Mediastinal Large B-cell Lymphoma (PMBCL)
- FL
- MCL
- Small Lymphocytic Lymphoma (SLL)
- Marginal Zone Lymphoma (MZL)
- Indolent B-cell Non-Hodgkin Lymphoma (iNHL)
- Aggressive B-cell Non-Hodgkin Lymphoma (aNHL)
Interventions
EpcoritamabBiological
Administered as specified in the treatment arm.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-Escalation: Dose Limiting Toxicity (DLT)Time frame: During the first cycle (28 days)
- Dose-Escalation: Number of Participants with Adverse Events (AEs)Time frame: From first dose until the end of the safety follow-up period (Up to 1 year)
- Expansion: Overall Response Rate (ORR)Time frame: Up to 1.5 years
- Dose-OPT DLBCL, FL and MCL: Percentage of Participants with =>Grade 2 Cytokine Release Syndrome (CRS) Events and All Grade CRS EventsTime frame: From first dose until 7 days after second full dose (Day 28 for DLBCL; Day 35 for FL; Day 28-35 for MCL)
Locations
85 sites in 15 countries. Site status is shown where the registry gives one.
Arizona Mayo Clinic
Phoenix, Arizona
University of California at San Francisco
San Francisco, California
Colorado Blood Cancer Institute
Denver, Colorado
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida
University of Iowa Hospital and Clinics
Iowa City, Iowa
Ochsner Medical Center
New Orleans, Louisiana
University of Michigan
Ann Arbor, Michigan
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan
University of Nebraska Medical Center
Omaha, Nebraska
Hackensack Meridian Health
Hackensack, New Jersey
The Cleveland Clinic Foundation
Cleveland, Ohio
OHSU Knight Cancer Institute
Portland, Oregon
Hillman Cancer Center
Pittsburgh, Pennsylvania
Rhode Island Hospital
Providence, Rhode Island
Medical University of South Carolina
Charleston, South Carolina
UT Southwestern
Dallas, Texas
MD Anderson Cancer Center
Houston, Texas
Monash Health
Clayton, Australia
Concord Hospital
Concord, Australia
St. Vincent Hospital
Fitzroy, Australia
Royal Brisbane and Women's Hospital
Herston, Australia
Royal Hobart Hospital RHH
Hobart, Australia
St. George Hospital
Kogarah, Australia
Cabrini Hospital
Malvern, Australia
Sir Charles Gairdner Hospital
Nedlands, Australia
Gold Coast Hospital
Southport, Australia
Westmead Hospital
Sydney, Australia
Tom Baker Cancer Care
Calgary, Canada
Toronto-Sunnybrook Regional Cancer Ctr
Toronto, Canada
Rigshospitalet
Copenhagen, Denmark
Odense University Hospital
Odense, Denmark
Vejle Hospital
Vejle, Denmark
Helsinki University Hospital
Helsinki, Finland
Kuopio University Hospital
Kuopio, Finland
Tampere University Hospital
Tampere, Finland
Hopital Henri Mondor
Créteil, France
CHU Montpellier
Montpellier, France
Hospital Saint-Louis
Paris, France
Hospices Civils de Lyon Centre Hospitalier Lyon Sud
Pierre-Bénite, France
Centre Henri Becquerel
Rouen, France
Showing 40 of 85 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.